Differential expression of PSMA and 18F-fluciclovine transporter genes in metastatic castrate-resistant and treatment-emergent small cell/neuroendocrine prostate cancer

被引：0
|
作者：
Chu, Carissa
Alshalalfa, Mohammed
Sjostrom, Martin
Zhao, Shuang
Herlemann, Annika
Chou, Jonathan
Baskin, Avi Lefridge
Mahal, Brandon Arvin Virgil
Spratt, Daniel Eidelberg
Cooperberg, Matthew R.
Small, Eric Jay
Aggarwal, Rahul Raj
Wong, Anthony C.
Porten, Sima P.
Hope, Thomas
Nguyen, Paul L.
Schaeffer, Edward M.
Carroll, Peter
Feng, Felix Y.
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
[2] Dana Farber Canc Inst, Vancouver, BC, Canada
[3] Lund Univ, Dept Pathol & Oncol, Lund, Sweden
[4] Univ Michigan, Ann Arbor, MI 48109 USA
[5] Harvard Radiat Oncol Program, Boston, MA USA
[6] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[7] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[8] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA
[9] Brigham & Womens Hosp, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA
[10] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
24
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Soft Tissue Response on 18F-Fluorocholine PET/CT in Metastatic Castrate-Resistant Prostate Cancer Treated With 223Ra-Dichloride A Possible Abscopal Effect?
    Kwee, Sandi A.
    Lim, John
    Coel, Marc N.
    CLINICAL NUCLEAR MEDICINE, 2017, 42 (11) : 868 - 871
  • [42] Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer
    Bhanvadia, Raj R.
    Woldu, Solomon L.
    Margulis, Vitaly
    Subramaniam, Rathan M.
    Bagrodia, Aditya
    CLINICAL GENITOURINARY CANCER, 2019, 17 (01) : E184 - E186
  • [43] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
  • [44] Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
    Emmett, Louise
    John, Nikeith
    Pathmanandavel, Sarennya
    Counter, William
    Ayers, Maria
    Sharma, Shikha
    Agrawal, Shikha
    Poole, Aron
    Hovey, Elizabeth
    Pranavan, Ganes
    Gedye, Craig
    Mallesara, Girish
    Guminski, Alex
    Lee, Adrian
    Stockler, Martin R.
    Hickey, Adam
    Eu, Peter
    Joshua, Anthony M.
    Crumbaker, Megan
    Nguyen, Andrew
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [45] Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)
    Emmett, Louise
    John, Nikeith
    Pathmanandavel, Sarennya
    Counter, William
    Ayers, Maria
    Sharma, Shikha
    Agrawal, Shikha
    Poole, Aron
    Hovey, Elizabeth
    Pranavan, Ganes
    Gedye, Craig
    Mallesara, Girish
    Guminski, Alex
    Lee, Adrian
    Stockler, Martin R.
    Hickey, Adam
    Eu, Peter
    Joshua, Anthony M.
    Crumbaker, Megan
    Nguyen, Andrew
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [46] Treatment-associated changes in whole-body metabolic tumor volume on 18F-fluorocholine PET/CT: potential prognostic value in castrate-resistant prostate cancer
    Kwee, Sandi
    Lim, John
    Kromer-Baker, Kathleen
    Miyazaki, Kyle
    Sato, Miles
    Lucuab-Fegurgur, Dayna
    Coel, Marc N.
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Differential Expression of Glucose Transporters and Hexokinases in Prostate Cancer with a Neuroendocrine Gene Signature: A Mechanistic Perspective for 18F-FDG Imaging of PSMA-Suppressed Tumors
    Bakht, Martin K.
    Lovnicki, Jessica M.
    Tubman, Janice
    Stringer, Keith F.
    Chiaramonte, Jonathan
    Reynolds, Michael R.
    Derecichei, Iulian
    Ferraiuolo, Rosa-Maria
    Fifield, Bre-Anne
    Lubanska, Dorota
    Oh, So Won
    Cheon, Gi Jeong
    Kwak, Cheol
    Jeong, Chang Wook
    Kang, Keon Wook
    Trant, John F.
    Morrissey, Colm
    Coleman, Ilsa M.
    Wang, Yuzhuo
    Ahmadzadehfar, Hojjat
    Dong, Xuesen
    Porter, Lisa A.
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61 (06) : 904 - 910
  • [48] Patterns of failure on Ga PSMA (GaPSMA) and F18 FDG (FDG) PET CT in a prospective phase 2 trial of 177Lu DKFZ PSMA 617 (LuPSMA) in men with castrate resistant metastatic prostate cancer (mCRPC)
    Joshua, Anthony M.
    Stricker, Phillip
    Epstein, Richard J.
    Ho, Bao
    Quoc Nguyen
    Kent, Robert
    Willowson, Kathy P.
    Hofman, Michael
    Violet, John A.
    Emmett, Louise
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer
    Irena Saarinen
    Ivan Jambor
    Mai Kim
    Anna Kuisma
    Jukka Kemppainen
    Harri Merisaari
    Olli Eskola
    Anna-Riina Koskenniemi
    Ileana Montoya Perez
    Peter Boström
    Pekka Taimen
    Heikki Minn
    EJNMMI Research, 9
  • [50] Correlation between 18F-1-amino-3-fluorocyclobutane-1-carboxylic acid (18F-fluciclovine) uptake and expression of alanine-serine-cysteine-transporter 2 (ASCT2) and L-type amino acid transporter 1 (LAT1) in primary prostate cancer
    Saarinen, Irena
    Jambor, Ivan
    Kim, Mai
    Kuisma, Anna
    Kemppainen, Jukka
    Merisaari, Harri
    Eskola, Olli
    Koskenniemi, Anna-Riina
    Perez, Ileana Montoya
    Bostrom, Peter
    Taimen, Pekka
    Minn, Heikki
    EJNMMI RESEARCH, 2019, 9 (1)
12345